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Background
For malaria parasites, exposure to drugs is now an
integral, human-induced, part of their ecology that
exerts substantial selective effects on their traits. Cur-
rently used drugs often do not eliminate transmission,
which enables evolution of traits that are beneficial for
parasites. The appearance and spread of resistance
mutations that protect parasites through direct interac-
tions with drug molecules are well documented and
often assumed to underlie treatment failures. However,
this is just one example of how parasites can minimise
their vulnerability to drugs. Other parasite traits (e.g.
growth rate, conversion rate, red blood cell preference)
that parasites have evolved independently of drugs can
also provide indirect protection from drugs. Both lab
a n df i e l dd a t as u g g e s tt h a ts uch traits can influence
parasite survival and transmission in drug treated
malaria infections.
Methods
We used a rodent malaria model (Plasmodium cha-
baudi) to test if virulence can confer protection to para-
sites in drug-treated infections. Mice were infected with
genetically similar virulent or avirulent genotypes
(CWvir orCWavir), with or without an additional com-
peting genotype (DK). Parasites were then exposed to
drugs (control, pyrimethamine or artemisinin, across
several doses and treatment regimes) and we compared
parasite survival, production of gametocytes and, in a
subset of infections, transmission to mosquitoes.
Results
We show virulent parasites better survived treatment
with pyrimethamine
1 or artemisinin, and produce more
gametocytes than genetically related avirulent parasites.
The survival and gametocyte production benefits for the
virulent parasites held fora range of drug doses, duration
of treatment and for drugs with different modes of
action.
Conclusions
Drug sensitivity can be virulence dependent, leading to a
survival and transmission advantage for virulent para-
sites. If these results are general across parasite geno-
types and species, this hasc o n s e q u e n c e sf o rt h e
evolutionary trajectories of parasites resulting from con-
tinued population-wide exposure to drugs
2. I will discuss
how to overcome the challenge of translating our
laboratory findings to natural infections in humans and
how to integrate our epidemiological and evolutionary
findings into a framework for malaria control.
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